10 Stocks on Jim Cramer’s Radar

8. REGENXBIO Inc. (NASDAQ:RGNX)

Number of Hedge Fund Holders: 35

During the lightning round, a caller asked if they should buy, sell, or hold REGENXBIO Inc. (NASDAQ:RGNX). Here’s what Mad Money’s host had to say:

“This thing just does nothing but go down, and it loses a ton of money. I can’t possibly recommend putting any money into that thing.”

REGENXBIO (NASDAQ:RGNX) is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform, with a pipeline that includes treatments for various genetic disorders. In 2024, Cramer commented:

“You have this REGENXBIO, which is a drug company which revealed that it might have something against Duchenne muscular dystrophy. That’s a terrible disease, very rare meaning they can charge very high prices for any treatment. That stock folded nearly 25% over two days in response to the news.”

For context, since the comment was made on February 8, 2024, REGENXBIO (NASDAQ:RGNX) stock went down more than 62%.